These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 38619583)
1. Impacts of liver macrophages, gut microbiota, and bile acid metabolism on the differences in iHFC diet-induced MASH progression between TSNO and TSOD mice. Igarashi N; Kasai K; Tada Y; Kani K; Kato M; Takano S; Goto K; Matsuura Y; Ichimura-Shimizu M; Watanabe S; Tsuneyama K; Furusawa Y; Nagai Y Inflamm Res; 2024 Jul; 73(7):1081-1098. PubMed ID: 38619583 [TBL] [Abstract][Full Text] [Related]
2. Impact of Vancomycin Treatment and Gut Microbiota on Bile Acid Metabolism and the Development of Non-Alcoholic Steatohepatitis in Mice. Kasai K; Igarashi N; Tada Y; Kani K; Takano S; Yanagibashi T; Usui-Kawanishi F; Fujisaka S; Watanabe S; Ichimura-Shimizu M; Takatsu K; Tobe K; Tsuneyama K; Furusawa Y; Nagai Y Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835461 [TBL] [Abstract][Full Text] [Related]
3. Antibiotic effects on gut microbiota modulate diet-induced metabolic dysfunction-associated steatohepatitis development in C57BL/6 mice. Takano S; Kani K; Kasai K; Igarashi N; Kato M; Goto K; Matsuura Y; Ichimura-Shimizu M; Watanabe S; Tsuneyama K; Furusawa Y; Nagai Y Genes Cells; 2024 Aug; 29(8):635-649. PubMed ID: 38864277 [TBL] [Abstract][Full Text] [Related]
4. Development of a novel mouse model of diet-induced nonalcoholic steatohepatitis-related progressive bridging fibrosis. Ichimura-Shimizu M; Omagari K; Yamashita M; Tsuneyama K Biosci Biotechnol Biochem; 2021 Mar; 85(4):941-947. PubMed ID: 33620426 [TBL] [Abstract][Full Text] [Related]
5. Dynamic changes of gut microbiota in mouse models of metabolic dysfunction-associated steatohepatitis and its transition to hepatocellular carcinoma. Wang YL; Liu C; Yang YY; Zhang L; Guo X; Niu C; Zhang NP; Ding J; Wu J FASEB J; 2024 Jul; 38(13):e23766. PubMed ID: 38967214 [TBL] [Abstract][Full Text] [Related]
6. Dynamics of Liver Macrophage Subsets in a Novel Mouse Model of Non-Alcoholic Steatohepatitis Using C57BL/6 Mice. Makiuchi N; Takano S; Tada Y; Kasai K; Igarashi N; Kani K; Kato M; Goto K; Matsuura Y; Ichimura-Shimizu M; Furusawa Y; Tsuneyama K; Nagai Y Biomedicines; 2023 Sep; 11(10):. PubMed ID: 37893033 [TBL] [Abstract][Full Text] [Related]
7. Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis. Rao Y; Kuang Z; Li C; Guo S; Xu Y; Zhao D; Hu Y; Song B; Jiang Z; Ge Z; Liu X; Li C; Chen S; Ye J; Huang Z; Lu Y Gut Microbes; 2021; 13(1):1-19. PubMed ID: 34030573 [TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of the intestinal flora in type 2 diabetes and nondiabetic mice. Horie M; Miura T; Hirakata S; Hosoyama A; Sugino S; Umeno A; Murotomi K; Yoshida Y; Koike T Exp Anim; 2017 Oct; 66(4):405-416. PubMed ID: 28701620 [TBL] [Abstract][Full Text] [Related]
9. Dietary cholesterol drives the development of nonalcoholic steatohepatitis by altering gut microbiota mediated bile acid metabolism in high-fat diet fed mice. Gao X; Lin X; Xin Y; Zhu X; Li X; Chen M; Huang Z; Guo H J Nutr Biochem; 2023 Jul; 117():109347. PubMed ID: 37031879 [TBL] [Abstract][Full Text] [Related]
11. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice. Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320 [TBL] [Abstract][Full Text] [Related]
12. Akkermansia muciniphila alleviates high-fat-diet-related metabolic-associated fatty liver disease by modulating gut microbiota and bile acids. Wu W; Kaicen W; Bian X; Yang L; Ding S; Li Y; Li S; Zhuge A; Li L Microb Biotechnol; 2023 Oct; 16(10):1924-1939. PubMed ID: 37377410 [TBL] [Abstract][Full Text] [Related]
13. Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway. Nie Q; Luo X; Wang K; Ding Y; Jia S; Zhao Q; Li M; Zhang J; Zhuo Y; Lin J; Guo C; Zhang Z; Liu H; Zeng G; You J; Sun L; Lu H; Ma M; Jia Y; Zheng MH; Pang Y; Qiao J; Jiang C Cell; 2024 May; 187(11):2717-2734.e33. PubMed ID: 38653239 [TBL] [Abstract][Full Text] [Related]
14. Characteristics of bone strength and metabolism in type 2 diabetic model Tsumura, Suzuki, Obese Diabetes mice. Tanaka H; Yamashita T; Yoneda M; Takagi S; Miura T Bone Rep; 2018 Dec; 9():74-83. PubMed ID: 30094297 [TBL] [Abstract][Full Text] [Related]
15. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome. Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146 [TBL] [Abstract][Full Text] [Related]
16. Yeast β-glucan reduces obesity-associated So SY; Wu Q; Leung KS; Kundi ZM; Savidge TC; El-Nezami H Am J Physiol Gastrointest Liver Physiol; 2021 Dec; 321(6):G639-G655. PubMed ID: 34643089 [TBL] [Abstract][Full Text] [Related]
17. Arabinoxylan combined with different glucans improve lipid metabolism disorder by regulating bile acid and gut microbiota in mice fed with high-fat diet. Chen H; Cheng J; Zhou S; Chen D; Qin W; Li C; Li H; Lin D; Zhang Q; Liu Y; Liu A; Luo Y Int J Biol Macromol; 2021 Jan; 168():279-288. PubMed ID: 33310093 [TBL] [Abstract][Full Text] [Related]
18. Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy. Wang Q; Bu Q; Xu Z; Liang Y; Zhou J; Pan Y; Zhou H; Lu L Clin Mol Hepatol; 2024 Jul; 30(3):515-538. PubMed ID: 38726504 [TBL] [Abstract][Full Text] [Related]
19. Dietary fat and gut microbiota interactions determine diet-induced obesity in mice. Kübeck R; Bonet-Ripoll C; Hoffmann C; Walker A; Müller VM; Schüppel VL; Lagkouvardos I; Scholz B; Engel KH; Daniel H; Schmitt-Kopplin P; Haller D; Clavel T; Klingenspor M Mol Metab; 2016 Dec; 5(12):1162-1174. PubMed ID: 27900259 [TBL] [Abstract][Full Text] [Related]
20. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice. Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]